Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

REVB | Revelation Biosciences Inc

Index- P/E- EPS (ttm)-0.11 Insider Own2.17% Shs Outstand6.30M Perf Week-5.94%
Market Cap4.32M Forward P/E- EPS next Y-1.43 Insider Trans23.48% Shs Float6.16M Perf Month-0.45%
Income2.33M PEG- EPS next Q-0.34 Inst Own12.79% Short Float / Ratio0.11% / 0.07 Perf Quarter-25.07%
Sales0.00M P/S- EPS this Y- Inst Trans-44.79% Short Interest0.01M Perf Half Y-52.72%
Book/sh1.81 P/B0.38 EPS next Y- ROA23.10% Target Price15.00 Perf Year-92.47%
Cash/sh2.49 P/C0.27 EPS next 5Y- ROE48.74% 52W Range0.64 - 17.55 Perf YTD-89.70%
Dividend- P/FCF- EPS past 5Y- ROI20.44% 52W High-96.09% Beta0.25
Dividend %- Quick Ratio3.45 Sales past 5Y0.00% Gross Margin- 52W Low7.12% ATR0.07
Employees6 Current Ratio3.45 Sales Q/Q- Oper. Margin0.00% RSI (14)40.99 Volatility9.08% 9.52%
OptionableNo Debt/Eq0.00 EPS Q/Q94.15% Profit Margin- Rel Volume0.35 Prev Close0.68
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume95.68K Price0.69
Recom1.00 SMA20-6.36% SMA50-9.26% SMA200-73.88% Volume33,210 Change0.82%
Aug-14-23 07:36AM
Aug-11-23 04:10PM
Jun-29-23 09:00AM
Jun-22-23 10:24AM
Jun-12-23 04:15PM
09:00AM Loading…
May-22-23 09:00AM
Mar-30-23 05:42PM
Mar-13-23 09:00AM
Mar-06-23 09:00AM
Feb-13-23 04:20PM
Feb-09-23 09:42AM
Feb-07-23 09:00AM
Jan-31-23 12:00PM
Jan-10-23 09:00AM
Nov-18-22 09:00AM
04:30PM Loading…
Nov-10-22 04:30PM
Oct-25-22 11:13AM
Oct-06-22 07:00AM
Aug-15-22 05:30PM
Jul-29-22 11:45AM
Jul-26-22 08:15AM
Jul-22-22 06:30PM
Jul-14-22 09:00AM
Jun-13-22 09:00AM
May-23-22 09:00AM
May-16-22 04:01PM
Apr-06-22 09:00AM
Mar-30-22 09:00AM
Mar-24-22 09:00AM
09:00AM Loading…
Mar-22-22 09:00AM
Mar-15-22 09:00AM
Mar-08-22 09:00AM
Feb-07-22 09:00AM
Jan-24-22 08:00AM
Jan-20-22 09:00AM
Jan-18-22 09:00AM
Jan-13-22 01:54PM
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TIDMARSH GEORGE FDirectorSep 18Sale0.744,0002,96039,348Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorSep 15Sale0.739,5006,93543,348Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorSep 14Sale0.7512,0009,00052,848Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorApr 18Buy1.1625,00029,00064,848Apr 19 06:00 PM
TIDMARSH GEORGE FDirectorApr 17Buy1.1626,50030,74039,848Apr 19 06:00 PM